Myriad Genetics (MYGN) Reports In-Line Q2 EPS, misses on revenue, provides guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $18.52 +0.65%
Revenue Growth %: +9.1%
Financial Fact:
Net income: -1.2M
Today's EPS Names:
IESC, FIZZ, DOMO, More
Revenue Growth %: +9.1%
Financial Fact:
Net income: -1.2M
Today's EPS Names:
IESC, FIZZ, DOMO, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $183.5 million versus the consensus estimate of $187.07 million.
GUIDANCE:
Myriad Genetics sees FY2023 EPS of ($0.36)-($0.24). Myriad Genetics sees FY2023 revenue of $730-750 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. economy adds 199,000 jobs in November
- Avid Bioservices (CDMO) Misses Q2 EPS by 9c, adjusts guidance
- RH (RH) shares tumble as 'frozen' housing market weighs on results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
